關於 ALLOZYNE INC
Allozyne was a clinical stage biotechnology company headquartered in Seattle's biotech and high tech innovation corridor. Allozyne was founded in 2005 by California Institute of Technology researchers, and was incubated by Accelerator Corporation. Its lead product candidate, AZ01, is a long acting interferon beta for the treatment of the relapsing remitting form of multiple sclerosis, a chronic degenerative disease characterized by demyelination of nerve fibers leading to severe nerve damage and increasing disability. Multiple sclerosis is estimated to affect 400,000 individuals in the US alone and 2.5 million worldwide. AZ01 is currently undergoing Phase I clinical trials in the US. Preclinical data indicates that AZ01 has the potential to be dosed once monthly compared to the current standard of care dosed anywhere from once daily to once per week.
Source: Wikipedia
產業Biotechnology
總部Seattle, WA
成立時間2005
法律形式C Corporation
狀態營運中
關鍵數據
法律資訊
| 法定名稱 | ALLOZYNE INC |
|---|---|
| 法律形式 | C Corporation |
| SEC CIK | 1345630在 SEC EDGAR 上查看 ↗ |
| 登記地址 | Seattle, WA |
| 狀態 | 營運中 |
來源: SEC EDGAR · 更新於 2026年11月14日